17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: A phase I study

Clinical Lymphoma and Myeloma

Volumn 6, Issue 6, 2006, Pages 500-501

  Shadad, Firas N ^a   Ramanathan, Ramesh K ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Geldanamycin analogues; Heat shock proteins; Ubiquitin proteasome pathways

Indexed keywords

17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SAFETY; HUMAN; LYMPHOMA; MAXIMUM TOLERATED DOSE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; SOLID TUMOR; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 33745888997     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.034     Document Type: Article

References (14)

1. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23:4152-4161.
2. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005; 11:3385-3391.
3. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to Hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42:273-279.
4. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002; 8:986-993.
5. Stebbins CE, Russo AA, Schneider C, et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997; 89:239-250.
6. Egorin MJ, Rosen DM, Wolff JH, et al. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998; 58:2385-2396.
7. Egorin MJ, Zuhowski EG, Rosen DM, et al. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001; 47:291-302.
8. Egorin MJ, Lagattuta TF, Hamburger DR, et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002; 49:7-19.
9. Smith V, Sausville EA, Camalier RF. 17-DMAG (NSC 707545), a water soluble geldanamycin analog, has superior in vivo antitumor activity compared to the hsp90 inhibitor 17-AAG. Eur J Cancer 2002; 38:S60.
10. Bonvini P, Gastaldi T, Falini B, et al. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002; 62:1559-1566.
11. June C, Fletcher M, Ledbetter J. Inhibition of tryosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc Natl Acad Sci USA 1990; 87:7722-7726.
12. Whitesell L, Mimaugh EG, DeCosta B. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994; 91:8324-8328.
13. Blum K. Phase I study of 17-AAG and bortezomib in patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. Available at: www.cancer.gov. Accessed October 24, 2005.
14. Page J, Heath J, Fulton R. Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamcyin (NSC-330507D) toxicity in rats. Proc Am Assoc Cancer Res 1997; 38:A2067.